Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 17/20 | 0.44 |
| ▸ | F11 | P03951 | 6/20 | 0.40 |
| ▸ | TPSB2 | P20231 | 6/20 | 0.40 |
| ▸ | PLAU | P00749 | 2/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | F7 | P08709 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23218969 | 0.91 | CFD (0.47) | CFDF11TPSB2PLAUKLKB1 | |
| SCHEMBL29853113 | 0.91 | CFD (0.47) | CFDF11TPSB2PLAUKLKB1 | |
| SCHEMBL29592635 | 0.91 | CFD (0.47) | CFDF11TPSB2PLAUKLKB1 | |
| SCHEMBL29591255 | 0.87 | CFD (0.47) | CFDF11TPSB2PLAUKLKB1 | |
| SCHEMBL23219213 | 0.87 | CFD (0.47) | CFDF11TPSB2PLAUKLKB1 | |
| SCHEMBL23218209 | 0.86 | CFD (0.46) | CFDF11TPSB2PLAUKLKB1 | |
| SCHEMBL29852507 | 0.86 | CFD (0.46) | CFDF11TPSB2PLAUKLKB1 | |
| SCHEMBL29592602 | 0.86 | CFD (0.46) | CFDF11TPSB2PLAUKLKB1 | |
| SCHEMBL23218718 | 0.85 | CFD (0.45) | CFDF11TPSB2PLAUKLKB1 | |
| SCHEMBL23218285 | 0.85 | CFD (0.45) | CFDF11TPSB2PLAUKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |